Introduction: Currently, 5% of the global adult population is affected by Alcohol Use Disorder (AUD), and alcohol consumption is linked to 3% of all deaths worldwide, being one of the main contributors to various diseases and mortality.Although the medications currently available demonstrate some efficacy, their adverse effects and the relatively long duration of treatment can hinder...
Ibogaine, a non-classical psychedelic, has gained increasing attention as a potential treatment for substance use disorders (SUD); however, a lack of commercial interest and safety-related concerns limit its clinical development. This cross-sectional study investigates the current landscape of clinical trials involving ibogaine, a non-classical psychedelic, focusing on its safety and efficacy....
Clinical ToxicologyMarch 1, 2025Ella P Edwards, Laurence A Gray, Muhammad E M O Elamin et al.2 citations
Ibogaine is a psychoactive alkaloid derived from the root bark of the West African shrub Tabernanthe iboga. It is not licensed in the United Kingdom but is used by individuals to alleviate drug or alcohol use. A retrospective analysis of telephone enquiries involving ibogaine between 1 January 2012 and 31 December 2022 to the United Kingdom National Poisons Information Service was performed....
Anecdotal reports and preliminary clinical trials suggest that the psychoactive alkaloid ibogaine and its active metabolite noribogaine have powerful anti-addictive properties, producing long-lasting therapeutic effects across a range of substance use disorders and co-occurring neuropsychiatric diseases such as depression and post-traumatic stress disorder. Here we report a gram-scale,...
Psychedelics show promise in treating psychiatric disorders. Therapeutic effects appear to involve activation of the 5-Hydroxytryptamine 2A receptor (5-HT2AR), a G protein-coupled receptor (GPCR). Several SNPs of the 5-HT2AR naturally occur, which are associated with differences in receptor function and altered responsiveness to treatments. New compounds suspected to act at the 5-HT2AR are...
The opioid crisis continues to exert a tremendous toll in North America, with existing interventions often falling short of addressing ongoing needs. Psychedelics are emerging as a possible alternative therapy for mental health and substance use disorders. This study aimed to gather insights on how people use or are considering using psychedelics to manage opioid use disorder (OUD), how these...
The 2024 North American Conference of Clinical Toxicology and the annual American College of Emergency Physicians Scientific Assembly yielded several thought-provoking ideas for emergency physicians, some that you should be employing and another, like this first one, that is not ready for the big time in the ED.
Despite national efforts to curb the opioid crisis, the clinical and societal challenges continue to grow. FDA-approved medications for opioid use disorder (OUD) are effective but are associated with high rates of treatment discontinuation and relapse. A collection of agents with acute effects on consciousness, collectively (if variably) categorized as 'psychedelics', have emerged as potential...
Frontiers in Immunology2025David Qixiang Chen, José Adalberto Inzunza Domínguez, Juan Manuel Valle Uzeta et al.3 citations
Multiple sclerosis (MS) is a debilitating neurodegenerative disease characterized by demyelination and neuronal loss. Traditional therapies often fail to halt disease progression or reverse neurological deficits. Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients...